Breaking the Stigma on Epilepsy: Manipal Hospital Sarjapur Road Hosted Health Talk on Purple Day
BENGALURU, India, April 3, 2025 /PRNewswire/ -- Epilepsy affects about 50 million…
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results…
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no…
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO
NEWARK, Calif.--(BUSINESS WIRE)--#AFIB--InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics…
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position
RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements,…